Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 36Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Pancreatic Neoplasms 4Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Advanced Breast Cancer 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Inflammation 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombosis 1Thromboembolism 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Primary Myelofibrosis 1Oligodendroglioma 1Neoplasms, Neuroepithelial 1Myeloproliferative Disorders 1

Interventions

Cisplatin 9pembrolizumab 7Irinotecan 7Radiotherapy 6Fluorouracil 6Docetaxel 5spartalizumab 4Oxaliplatin 4130-nm albumin-bound paclitaxel 4Nivolumab 3Carboplatin 3toripalimab 2tislelizumab 2elgemtumab 2durvalumab 2Radiation 2Paclitaxel 2Leucovorin 2Gemcitabine 2Drug Therapy 2vandetanib 1tremelimumab 1ribociclib 1palbociclib 1obinutuzumab 1nedaplatin 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1dalpiciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Squamous Cell Carcinoma × palbociclib × Clear all
NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

West China Hospital

Phase 1 Active not recruiting
6 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡